Satellos BioScience CEO Frank Gleeson joined Steve Darling from Proactive to share more details about the company that is developing lifechanging medicines to treat degenerative muscle conditions. Gleeson telling Proactive the company has a belief its therapeutic approach represents a potential disease modifying treatment for Duchenne and other dystrophies. The company has created a proprietary discovery platform called MyoReGenXTM, which is used to identify disease situations where deficits in muscle stem cell polarity and regeneration occur
Satellos BioScience files patents as company looks to help in the treatment of Duchenne
